The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khanna, R
Right arrow Articles by Khanna, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khanna, R
Right arrow Articles by Khanna, K.

The Journal of Immunology, Vol 159, Issue 12 5782-5785, Copyright © 1997 by American Association of Immunologists

CUTTING EDGE

Cutting Edge: Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells

R Khanna, L Cooper, N Kienzle, DJ Moss, SR Burrows and KK Khanna
EBV Unit, Queensland Institute of Medical Research, Herston, Australia. rajivK@qimr.edu.au

Cells from the EBV-associated tumor, Burkitt's lymphoma (BL), are known to be highly inefficient at endogenous processing of class I-restricted CTL epitopes due to a consistent loss of peptide transporters (TAP) and MHC expression. We investigated the potential of CD40 engagement to up- regulate the expression of class I-processing genes and to enhance the immunogenicity of these malignant cells toward EBV-specific CTLs. Here we show that engagement of CD40 Ag with soluble CD40 ligand (CD40L) up- regulates TAP-1 and HLA class I expression on BL cells. More importantly, analysis of the Ag-processing function, using a recombinant vaccinia virus to transiently express the EBV nuclear Ags, revealed that CD40L-treated BL cells consistently processed endogenously synthesized viral Ags for recognition by HLA class I- restricted, virus-specific CTLs. These findings raise the possibility that CD40L treatment of tumor cells might be exploited in immunotherapeutic protocols.


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
A. Moschonas, M. Kouraki, P. G. Knox, E. Thymiakou, D. Kardassis, and A. G. Eliopoulos
CD40 Induces Antigen Transporter and Immunoproteasome Gene Expression in Carcinomas via the Coordinated Action of NF-{kappa}B and of NF-{kappa}B-Mediated De Novo Synthesis of IRF-1
Mol. Cell. Biol., October 15, 2008; 28(20): 6208 - 6222.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. O. Guerreiro-Cacais, M. Uzunel, J. Levitskaya, and V. Levitsky
Inhibition of Heavy Chain and {beta}2-Microglobulin Synthesis as a Mechanism of Major Histocompatibility Complex Class I Downregulation during Epstein-Barr Virus Replication
J. Virol., February 1, 2007; 81(3): 1390 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Murugaiyan, R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha
Functional Dichotomy in CD40 Reciprocally Regulates Effector T Cell Functions
J. Immunol., November 15, 2006; 177(10): 6642 - 6649.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
H. Yoneyama, K. Matsuno, E. Toda, T. Nishiwaki, N. Matsuo, A. Nakano, S. Narumi, B. Lu, C. Gerard, S. Ishikawa, et al.
Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs
J. Exp. Med., August 1, 2005; 202(3): 425 - 435.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al.
Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis
J. Immunol., January 1, 2005; 174(1): 41 - 50.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. P. Lee, J. M. Brooks, H. Al-Jarrah, W. A. Thomas, T. A. Haigh, G. S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J. L. Yates, et al.
CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1
J. Exp. Med., May 17, 2004; 199(10): 1409 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Clatza, L. C. Bonifaz, D. A. A. Vignali, and J. Moreno
CD40-Induced Aggregation of MHC Class II and CD80 on the Cell Surface Leads to an Early Enhancement in Antigen Presentation
J. Immunol., December 15, 2003; 171(12): 6478 - 6487.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. A. Tolba, W. J. Bowers, S. P. Hilchey, M. W. Halterman, D. F. Howard, R. E. Giuliano, H. J. Federoff, and J. D. Rosenblatt
Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia
Blood, July 15, 2001; 98(2): 287 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
D. Chaussabel, F. Jacobs, J. de Jonge, M. de Veerman, Y. Carlier, K. Thielemans, M. Goldman, and B. Vray
CD40 Ligation Prevents Trypanosoma cruzi Infection through Interleukin-12 Upregulation
Infect. Immun., April 1, 1999; 67(4): 1929 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. V. Henriquez, E. Floettmann, M. Salmon, M. Rowe, and A. B. Rickinson
Differential Responses to CD40 Ligation Among Burkitt Lymphoma Lines That Are Uniformly Responsive to Epstein-Barr Virus Latent Membrane Protein 1
J. Immunol., March 15, 1999; 162(6): 3298 - 3307.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.